Fentora Articles
US FDA approves Actavis generic copy of GSK’s Valtrex and Hi-Tech’s lidocaine; Cephalon wins Fentora patent case
25 March 2011
Cancer pain drug market, fueled by opioids, will increase from $2.3 billion in 2008 to $3.7 billion in 2018
25 November 2009
Cephalon swings back to profit in 3rd qtr
1 December 2008
Delay for Cephalon's Fentora sNDA
29 September 2008
Cephalon exceeds guidance for 2nd qtr
11 August 2008
Cephalon sues Watson over Fentora
9 June 2008
Watson filed for generic Fentora
5 May 2008
FDA to consider Fentora sNDA on May 6
4 February 2008
Cephalon files Fentora sNDA with FDA
19 November 2007
FDA warns on risks of improper Fentora use
8 October 2007
Cephalon clarifies patient selection after Fentora AE reports
24 September 2007
Strong Ph III data for Cephalon's Fentora
20 August 2007
Cephalon's 1st-qtr income soars to $75M
14 May 2007
Fentora performs well in Ph III pain trial
7 May 2007
Cephalon files fentanyl buccal tablet with EMEA
2 April 2007
Waxman investigates marketing practices
12 March 2007
Stock Commentary - New York week to Feb 19, 2007
26 February 2007
Beijing Med-Pharma in deal with Cephalon
18 December 2006
Fentora Ph III pain study produces positive data
23 October 2006
US FDA approves Cephalon's Fentora
2 October 2006
Fentora viewed as approvable by US FDA
10 July 2006
Stock Commentary - New York week to July 3, 2006
10 July 2006
Showing 1-24 of 24 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
